A.R.T. Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

A.R.T. Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-6,183	Closed	-$382K	–	339
2019 Q4	$382K	Sell	6,183 -10,964	-64%	-$680K	0.02%	948
2019 Q3	$1.03M	Buy	+17,147	New	+$1.27M	0.05%	537
2018 Q2	–	Sell	-3,446	Closed	-$278K	–	1513
2018 Q1	$278K	Buy	+3,446	New	+$265K	0.01%	1156
2017 Q2	–	Sell	-15,500	Closed	-$477K	–	1496
2017 Q1	$477K	Buy	15,500 +7,500	+94%	+$234K	0.02%	822
2016 Q4	$268K	Buy	+8,000	New	+$229K	0.02%	974
2016 Q2	–	Sell	-34,915	Closed	-$1.02M	–	1432
2016 Q1	$1.02M	Buy	34,915 +24,500	+235%	+$682K	0.05%	577
2015 Q4	$343K	Buy	+10,415	New	+$339K	0.02%	1002
2015 Q2	–	Sell	-89,103	Closed	-$2.73M	–	1535
2015 Q1	$2.73M	Buy	89,103 +70,756	+386%	+$2.75M	0.09%	285
2014 Q4	$932K	Buy	+18,347	New	+$821K	0.03%	670

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

A.R.T. Advisors's ENTA Position: Q1 2020 in Review

A.R.T. Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q1 2020, closing a stake of 6,183 shares — an estimated $382K sold.

A.R.T. Advisors first reported a position in ENTA in Q4 2014 and held it in 9 quarters. The position peaked at $2.73M in Q1 2015. 156 funds tracked by Wall St. Rank hold ENTA as of Q1 2020.

A.R.T. Advisors reported no remaining Enanta Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
A.R.T. Advisors sold 6,183 Enanta Pharmaceuticals shares in Q1 2020, an estimated $382K.
A.R.T. Advisors first reported a position in Enanta Pharmaceuticals in Q4 2014 and held it in 9 quarters.
A.R.T. Advisors's Enanta Pharmaceuticals position peaked at $2.73M in Q1 2015.
156 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.